DelveInsight’s, “Anaplastic Thyroid Cancer Pipeline Insight 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Anaplastic Thyroid Cancer pipeline landscape. It covers the Anaplastic Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anaplastic Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
- DelveInsight’s Anaplastic Thyroid Cancer pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
- The leading companies working in the Anaplastic Thyroid Cancer Market include Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics Inc., Merck & Co., Iovance Biotherapeutics Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.
- Promising Anaplastic Thyroid Cancer Pipeline Therapies in the various stages of development include HLX208, Lenvatinib, Nivolumab, Trametinib, Paclitaxel, Durvalumab, Tremelimumab, and others.
- November 2023: AffyImmune Therapeutics Inc. announced a study of Phase 1 clinical trials for AIC100 CAR T Cells. The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed. The primary objective of this study is to assess the safety and tolerability of AIC100 CAR T Cells and determine the recommended Phase 2 dose of AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer and in patients with anaplastic thyroid cancer that are BRAF wild-type, including newly diagnosed, or BRAF mutant anaplastic thyroid cancer after failure of BRAF mutant specific therapy.
- October 2023: Ledien University Medical Center announced a study of Phase 2 clinical trials for dabrafenib/trametinib. Most patients present with a rapid progressive mass in the neck with progressive complaints like dyspnoea, dysphagia or pain. The risk of suffocation is the main reason for rapid surgical intervention, but we know from literature that an oncological resection with clear margins is seldomly achieved. Some patients deteriorate that fast after surgery that radiation therapy and/or chemotherapy is not feasible anymore. Patients with BRAF-mutated ATC already have shown to benefit from targeted BRAF/MEK inhibition. This study aims to increase the number of patients that undergo a successful R0 tumor resection after neo-adjuvant BRAF/MEK inhibitor treatment.
- October 2023: Cancer Research UK announced a study of Phase 2 & 3 clinical trials for Vemurafenib and Cobimetinib. This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma.
- October 2023: M.D. Anderson Cancer Center announced a study of Phase 2 clinical trials for Fludarabine, Cyclophosphamide, Ipilimumab and Aldesleukin. This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed).
- September 2023: Memorial Sloan Kettering Cancer Center announced a study of Phase 2 clinical trials for Avutometinib and Defactinib. The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects.
- August 2023: Standford University announced a study of Phase 2 clinical trials for Pembrolizumab (Keytruda). This is a single-arm, open-label trial designed to evaluate the activity of pembrolizumab therapy in anaplastic thyroid cancer in patients with no curative alternative therapy. Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death.
Request a sample and discover the recent advances in Anaplastic Thyroid Cancer Treatment Drugs @ Anaplastic Thyroid Cancer Pipeline Report
In the Anaplastic Thyroid Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anaplastic Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Anaplastic Thyroid Cancer Overview
Anaplastic thyroid cancer, or ATC, is a type of thyroid cancer. The thyroid is a gland located in the front of your neck, just below the Adam’s apple. It is responsible for sending the hormones to the rest of the body. ATC is different than other types of thyroid cancers because ATC invades other parts of the body very quickly. This type of cancer usually affects people over the age of 60. ATC can also be called anaplastic thyroid carcinoma.
Find out more about Anaplastic Thyroid Cancer Therapeutics Assessment @ Anaplastic Thyroid Cancer Preclinical and Discovery Stage Products
Anaplastic Thyroid Cancer Emerging Drugs Profile
- Sapanisertib: Takeda
- HLX208: Shanghai Henlius Biotech
Anaplastic Thyroid Cancer Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Anaplastic Thyroid Cancer. The Anaplastic Thyroid Cancer companies which have their Anaplastic Thyroid Cancer drug candidates in the most advanced stage, i.e. phase II include, Takeda.
DelveInsight’s Anaplastic Thyroid Cancer pipeline report covers around 8+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Anaplastic Thyroid Cancer Pipeline Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Learn more about the emerging Anaplastic Thyroid Cancer Pipeline Therapies @ Anaplastic Thyroid Cancer Clinical Trials Assessment
Scope of the Anaplastic Thyroid Cancer Pipeline Report
- Coverage- Global
- Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics Inc., Merck & Co., Iovance Biotherapeutics Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.
- Anaplastic Thyroid Cancer Pipeline Therapies- HLX208, Lenvatinib, Nivolumab, Trametinib, Paclitaxel, Durvalumab, Tremelimumab, and others.
Dive deep into rich insights for new drugs for Anaplastic Thyroid Cancer Treatment, Visit @ Anaplastic Thyroid Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Anaplastic Thyroid Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Anaplastic Thyroid Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Sapanisertib: Takeda
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AIC100: AffyImmune Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Anaplastic Thyroid Cancer Key Companies
- Anaplastic Thyroid Cancer Key Products
- Anaplastic Thyroid Cancer- Unmet Needs
- Anaplastic Thyroid Cancer- Market Drivers and Barriers
- Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
- Anaplastic Thyroid Cancer Analyst Views
- Anaplastic Thyroid Cancer Key Companies
- Appendix
For further information on the Anaplastic Thyroid Cancer Pipeline therapeutics, reach out to Anaplastic Thyroid Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/type-1-diabetes-market